ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1299

Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study

Edward Keystone1, Juan Xiong2, Deborah Weber3 and Ye Sun4, 1The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Treatment options

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a biologic with a different mode of action such as rituximab (RTX) or abatacept (ABA). The relative effectiveness of these approaches has not been determined in head-to-head trials. Evidence from real-world experience would help to guide treatment decisions for TNF-IR patients.

Methods: This was a retrospective chart review of patients from a single site (Rebecca MacDonald Center) with ACR-defined RA who initiated RTX or ABA after failure of at least one TNFi. The relative effectiveness of RTX and ABA was evaluated by analyzing drug survival distribution. Kaplan-Meier survival curves were compared using the log rank test (p-values <0.05 indicated statistical significance).

Results: The study cohort comprised 61 patients, of whom 37 and 24 were treated with RTX and ABA, respectively. In the RTX group, 10 patients had also received prior therapy with ABA. Demographics and disease characteristics were generally similar in the two groups, although RTX patients had higher disease activity compared with ABA patients (mean CDAI: RTX 32.5 vs ABA 26.9) and had received more prior TNFis (1.8 vs 1.7) and/or ABA (2.1 vs 1.7). After excluding the 10 RTX patients who had received prior ABA, survival rates over time were generally better with RTX vs ABA (table).

Estimated survival rates

Time (years)

RTX (n=27)

ABA (n=24)

0.5

0.92

0.83

1.0

0.79

0.74

1.5

0.74

0.54

2.0

0.68

0.54

3.0

0.68

0.54

4.0

0.68

0.41

Overall survival distribution (figure) was not significantly different between the RTX and ABA groups (p=0.658); however, RTX patients who had also failed ABA had significantly reduced survival compared with those who had not received ABA (p=0.015).

Overall survival distribution

Stratification of survival data according to number of prior TNFi failures indicated that RTX (excluding patients with prior ABA) was superior to ABA among patients who had failed 3 TNFis. Survival was also numerically greater with RTX vs ABA in patients who had failed 1 prior TNFi. Finally, survival was better on both RTX and ABA when compared with that seen in a separate cohort of patients (n=88) who received a second TNFi after first TNFi failure.

Conclusion: These results from real-life practice suggest that in RA patients who have failed one or more TNFi, RTX may have better long-term survival than either ABA or an alternative TNFi. Prior ABA appears to reduce the efficacy of RTX. Further data are needed.


Disclosure:

E. Keystone,

Abbott, Amgen, AstraZeneca, Bristol-Meyers Squibb, Centocor, Roche, Genzyme, Merck, Novartis, Pfizer, UCB,

2,

Abbott, AstraZeneca, Biotest, Bristol-Meyers Squibb, Centocor, Roche, Genentech, Merck, Nycomed, Pfizer, UCB,

5;

J. Xiong,
None;

D. Weber,
None;

Y. Sun,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rituximab-versus-abatacept-in-rheumatoid-arthritis-patients-with-an-inadequate-response-to-prior-biologic-therapy-a-retrospective-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.